The Medicines Patent Pool statement on potential extension of its mandate to hepatitis C and tuberculosis
The MPP acknowledges the recent response and input from various civil society organisations and treatment groups on the Foundation’s ongoing assessments to determine the feasibility of extending its mandate to include medicines for hepatitis C (HCV) and tuberculosis (TB).
At the request of the UNITAID Executive Board, MPP has been exploring whether, and to what extent, its current model could be adapted to improve access to products in these two disease areas. The MPP has already created important opportunities for increasing access for people living with HIV in developing countries through voluntary licensing agreements and patent sharing. As in case of HIV, HCV and TB disproportionately affect patients in low- and middle-income nations and novel thinking and complementary initiatives are needed to spur innovation and access for new products in order to address the unmet needs of patients in these countries.
The MPP commissioned independent feasibility studies to review the case for MPP entry into HCV and TB. These studies are currently being reviewed by the MPP’s governance bodies and they will serve as a starting point for the MPP’s own proposals to be provided to UNITAID later in the year after appropriate consideration and consultation. In line with the Foundation’s commitment to transparency, the findings of these studies will be shared with stakeholder groups as part of the consultation process that the MPP will undertake over the coming months, including with civil society and patient groups active in these treatment areas.
Source: Medicines Patent Pool